<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02675478</url>
  </required_header>
  <id_info>
    <org_study_id>AC220-A-J101</org_study_id>
    <nct_id>NCT02675478</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of Quizartinib</brief_title>
  <official_title>A Phase 1, Open-Label, Dose Escalation Study of Quizartinib, An Oral FLT3 Inhibitor, in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of
      quizartinib for Japanese acute myeloid leukemia (AML) subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">November 13, 2018</completion_date>
  <primary_completion_date type="Actual">November 13, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of subjects experiencing adverse events</measure>
    <time_frame>first dose to follow-up, approximately 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of quizartinib and its active metabolite</measure>
    <time_frame>Cycle 1: Days 1, 2, 4, 8, 11, 15, 16, 18, 22, 28; Cycle 2 and on: Days 1, 15</time_frame>
    <description>Evaluate the pharmacokinetics of quizartinib and its active metabolite, AC886 by Cmax, Tmax, AUCtau, Cmax,ss, Ctrough, Tmax,ss, AUCtau,ss.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of quizartinib and its active metabolite</measure>
    <time_frame>Cycle 1: Days 1, 2, 4, 8, 11, 15, 16, 18, 22, 28; Cycle 2 and on: Days 1, 15</time_frame>
    <description>Evaluate the pharmacokinetics of quizartinib and its active metabolite, AC886 by Cmax, Tmax, AUCtau, Cmax,ss, Ctrough, Tmax,ss, AUCtau,ss.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCtau of quizartinib and its active metabolite</measure>
    <time_frame>Cycle 1: Days 1, 2, 4, 8, 11, 15, 16, 18, 22, 28; Cycle 2 and on: Days 1, 15</time_frame>
    <description>Evaluate the pharmacokinetics of quizartinib and its active metabolite, AC886 by Cmax, Tmax, AUCtau, Cmax,ss, Ctrough, Tmax,ss, AUCtau,ss.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss of quizartinib and its active metabolite</measure>
    <time_frame>Cycle 1: Days 1, 2, 4, 8, 11, 15, 16, 18, 22, 28; Cycle 2 and on: Days 1, 15</time_frame>
    <description>Evaluate the pharmacokinetics of quizartinib and its active metabolite, AC886 by Cmax, Tmax, AUCtau, Cmax,ss, Ctrough, Tmax,ss, AUCtau,ss.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ctrough of quizartinib and its active metabolite</measure>
    <time_frame>Cycle 1: Days 1, 2, 4, 8, 11, 15, 16, 18, 22, 28; Cycle 2 and on: Days 1, 15</time_frame>
    <description>Evaluate the pharmacokinetics of quizartinib and its active metabolite, AC886 by Cmax, Tmax, AUCtau, Cmax,ss, Ctrough, Tmax,ss, AUCtau,ss.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax,ss of quizartinib and its active metabolite</measure>
    <time_frame>Cycle 1: Days 1, 2, 4, 8, 11, 15, 16, 18, 22, 28; Cycle 2 and on: Days 1, 15</time_frame>
    <description>Evaluate the pharmacokinetics of quizartinib and its active metabolite, AC886 by Cmax, Tmax, AUCtau, Cmax,ss, Ctrough, Tmax,ss, AUCtau,ss.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCtau,ss of quizartinib and its active metabolite</measure>
    <time_frame>Cycle 1: Days 1, 2, 4, 8, 11, 15, 16, 18, 22, 28; Cycle 2 and on: Days 1, 15</time_frame>
    <description>Evaluate the pharmacokinetics of quizartinib and its active metabolite, AC886 by Cmax, Tmax, AUCtau, Cmax,ss, Ctrough, Tmax,ss, AUCtau,ss.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FMS-like tyrosine kinase-3 / internal tandem duplication FLT3/ITD allelic ratio</measure>
    <time_frame>Cycle 1: Days 1, 2, 8, 15</time_frame>
    <description>Exploratory assessment of quizartinib-related biomarkers such as FLT3-ITD allelic ratio, PIA assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PIA assessment</measure>
    <time_frame>Cycle 1: Days 1, 2, 8, 15</time_frame>
    <description>Exploratory assessment of quizartinib-related biomarkers such as FLT3-ITD allelic ratio, PIA assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bone marrow findings</measure>
    <time_frame>Cycle 1: Days 15, 28; Cycle 2 and on: Day 28</time_frame>
    <description>Exploratory analyses of tumor response to quizartinib based on bone marrow findings, absolute neutrophil count, and platelet count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>absolute neutrophil count</measure>
    <time_frame>Cycle 1: Days 15, 28; Cycle 2 and on: Day 28</time_frame>
    <description>Exploratory analyses of tumor response to quizartinib based on bone marrow findings, absolute neutrophil count, and platelet count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>platelet count</measure>
    <time_frame>Cycle 1: Days 15, 28; Cycle 2 and on: Day 28</time_frame>
    <description>Exploratory analyses of tumor response to quizartinib based on bone marrow findings, absolute neutrophil count, and platelet count.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Relapsed AML</condition>
  <condition>Refractory AML</condition>
  <arm_group>
    <arm_group_label>AC220</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This study will follow a mCRM (modified continual reassessment method) + EWOC (Escalation with Overdose Control) design.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC220</intervention_name>
    <arm_group_label>AC220</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Relapsed or refractory AML

          -  AML for which no standard treatment is available

          -  ECOG Performance Status (PS) of 0 to 2

        Exclusion Criteria:

          -  Acute Promyelocytic Leukemia

          -  chronic myelogenous leukemia in blast phase (BCR-ABL fusion gene positive)

          -  History of other malignancies within 3 years prior to enrollment, except curatively
             treated in-situ carcinoma, AML, or MDS.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>February 2, 2016</study_first_submitted>
  <study_first_submitted_qc>February 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2016</study_first_posted>
  <last_update_submitted>February 8, 2019</last_update_submitted>
  <last_update_submitted_qc>February 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>phase 1</keyword>
  <keyword>oncology</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/daiichi-sankyo/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

